On Friday, Shares of Summit Materials Inc (NYSE:SUM), added 0.50% and closed at $23.99 in the last trading session. The last trading range of the stock ranges between $23.06 and $24.19. The company’s Market capitalization is $2.51 Billion with the total Outstanding Shares of 75.57 million. Summit Materials, Inc. (NYSE:SUM, “Summit”) declared recently the pricing of a secondary offering of 16,614,949 shares of Class A common stock by certain selling stockholders, counting associates of The Blackstone Group L.P., at a public offering price of $22.10 per share. The offering is expected to close on November 15, 2016, subject to customary closing conditions.
Summit did not offer any shares of Class A common stock in the offering and will not receive any proceeds from Hot Stocks:
the sale of shares in this offering.
Barclays Capital Inc. is serving as sole book-running manager for the offering.
Technical Analysis: During the 52-week trading session the minimum price at which share price traded, registered at $13.12 and reached to max level of $24.55. The EPS of company is strolling at 0.84.
Shares of Celgene Corporation (NASDAQ:CELG), dropped -1.33% and closed at $119.45 in the last trading session. The last trading range of the stock ranges between $116.85 and $120.60. The company’s Market capitalization is $91.37 Billion with the total Outstanding Shares of 775.20 million. Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID to treat multiple myeloma; and OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, ankylosing spondylitis, Behçet’s disease, atopic dermatitis, and ulcerative colitis. The companys products also include VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, in addition to acute myeloid leukemia (AML); THALOMID for the patients with multiple myeloma and erythema nodosum leprosum; ISTODAX to treat cutaneous and peripheral T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN products. Its clinical stage products include OTEZLA for the treatment of various immune-inflammatory diseases; sotatercept for the treatment of renal anemia, beta-thalassemia and MDS; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; PDA-002 for the treat diabetic foot ulcers and peripheral neuropathy; and PNK-007 for hematological malignancies treatment.
Technical Analysis: During the 52-week trading session the minimum price at which share price traded, registered at $93.05 and reached to max level of $127.00. The EPS of company is strolling at 2.64.